Nicholas J. Tursi - Concepedia

Author

Nicholas J. Tursi

The Wistar Institute ORCID

Also Known As

Nicholas J Tursi, Nicholas J. Tursi, Nicholas Tursi

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

The Wistar Institute Inovio Pharmaceuticals (United States)University of Pennsylvania University of Manitoba Public Health Agency of Canada

About

Nicholas J. Tursi is an author at The Wistar Institute specializing in immunology, medicine, and immunodominance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	78
2	Immunology	2	2	78
3	Cell Biology	1	1	16
4	Humoral Immunity	1	1	62
5	Immunodominance	1	1	62

Nicholas J. Tursi

Publications

965

Citations

H-Index

Page 1

	Year	Citations
Immunogenicity of a DNA vaccine candidate for COVID-19 Trevor R.F. Smith, Ami Patel, Stephanie Ramos, Nature Communications	2020	635
Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model Ami Patel, Jewell Walters, Emma L. Reuschel, Adaptive Immune SystemImmunologyImmunodominanceCd4 T Cell ResponsesCovid-19	2020	62
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model Ami Patel, Jewell Walters, Emma L. Reuschel, Cell Reports Medicine	2021	51
A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote <i>In Vivo</i> Tumor Control Ziyang Xu, Neethu Chokkalingam, Edgar Tello‐Ruiz, Cancer Immunology Research	2020	28
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection Kylie M. Konrath, Kevin Liaw, Yuanhan Wu, Cell Reports	2022	28
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2 Elizabeth M. Parzych, Jianqiu Du, Ali Ali, Nature Communications	2022	27
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers Christian J. Maine, Shigeki J. Miyake‐Stoner, Darina Spasova, Nature Communications	2025	26
A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens E. Gary, Bryce M. Warner, Elizabeth M. Parzych, iScience	2021	19
Uropathogenic Escherichia coli Infection Compromises the Blood-Testis Barrier by Disturbing mTORC1-mTORC2 Balance Yongning Lu, Miao Liu, Nicholas J. Tursi, Frontiers in Immunology	2021	18
Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo E. Gary, Nicholas J. Tursi, Bryce M. Warner, Cell Reports Medicine	2022	18

Page 1